Short-term Outcomes of Water Vapor Therapy (Rezum) for BPH/LUTS in the First Czech Cohort

WASSERBAUER, Roman, Dalibor PACIK, Gabriel VARGA, Vítězslav VÍT, Jiří JARKOVSKÝ and Michal FEDORKO. Short-term Outcomes of Water Vapor Therapy (Rezum) for BPH/LUTS in the First Czech Cohort. UROLOGY JOURNAL. TEHRAN: UROL & NEPHROL RES CTR-UNRC, 2021, vol. 18, No 6, p. 699-702. ISSN 1735-1308. Available from: https://dx.doi.org/10.22037/uj.v18i.6843.

Basic information

• Original name: Short-term Outcomes of Water Vapor Therapy (Rezum) for BPH/LUTS in the First Czech Cohort
• Authors: WASSERBAUER, Roman (203 Czech Republic, belonging to the institution), Dalibor PACIK (203 Czech Republic), Gabriel VARGA (703 Slovakia, belonging to the institution), Vítězslav VÍT (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution) and Michal FEDORKO (703 Slovakia, belonging to the institution).
• Edition: UROLOGY JOURNAL, TEHRAN, UROL & NEPHROL RES CTR-UNRC, 2021, 1735-1308.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30217 Urology and nephrology
• Country of publisher: Islamic Republic of Iran
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 1.555
• RIV identification code: RIV/00216224:14110/21:00124058
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.22037/uj.v18i.6843
• UT WoS: 000747743200004
• Keywords in English: benign prostatic hyperplasia; lower urinary tract symptoms; minimally invasive treatment; vapor; water
• Tags: 14110225, 14119612, rivok
• Tags: International impact, Reviewed

Abstract

Purpose: To evaluate the short-term results of water vapor therapy (RezUm) for BPH/LUTS in the first cohort of Czech patients. Materials and methods: Patients with BPH and moderate to severe LUTS (N = 76) who underwent RezUm treatment from December 2019 to July 2020 were included in the prospective study. Prior to the procedure, they completed the IPSS and OABv8 questionnaires and underwent uroflowmetry, transrectal ultrasound of the prostate, and PSA sampling. The parameters before and 3 months after the procedure were compared and statistically evaluated. Results: The study protocol was completed by 92% of patients (N = 70). We observed a significant increase in Qmax (median 17.7 vs. 8.8 mL/s, P < .001), Qave (9 vs. 4.5 mL/s, P = .001) and voided volume (241 vs. 171 mL, P < .001) and a significant reduction in post-void residual (average 17.5 vs. 67.7 mL), prostate volume (39.3 vs. 62.3 mL) and total PSA (median 1.9 vs. 2.5 ng/mL, resp. P values < .001). There was also a significant decrease in OABv8 score (average 7.6 vs. 16.6, P < .001) and IPSS QoL (1.6 vs. 4.0, P = .037). The improvement in the IPSS score was apparent, yet statistically insignificant (6.8 vs. 16, P = .079). Conclusion: Water vapor therapy is an effective and safe method of BPH/LUTS treatment in the short-term.